Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q2 2025 value amounting to -$26000.0.

  • Catalyst Pharmaceuticals' Cash from Investing Activities fell 16000.0% to -$26000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$114000.0, marking a year-over-year increase of 9970.61%. This contributed to the annual value of -$556000.0 for FY2024, which is 9981.06% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$26000.0 for Q2 2025, which was down 16000.0% from -$88000.0 recorded in Q4 2024.
  • Catalyst Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$10000.0 during Q2 2024, with a 5-year trough of -$162.4 million in Q1 2023.
  • For the 5-year period, Catalyst Pharmaceuticals' Cash from Investing Activities averaged around -$23.5 million, with its median value being -$199000.0 (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 7021590.91% in 2023, then soared by 9987.74% in 2024.
  • Catalyst Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$41000.0 in 2021, then plummeted by 221.95% to -$132000.0 in 2022, then crashed by 28928.79% to -$38.3 million in 2023, then surged by 99.77% to -$88000.0 in 2024, then soared by 70.45% to -$26000.0 in 2025.
  • Its Cash from Investing Activities stands at -$26000.0 for Q2 2025, versus -$88000.0 for Q4 2024 and -$259000.0 for Q3 2024.